Stifel on Immunic Inc. (IMUX): 'Overall, we see a number of potential avenues for differentiation for VidoCa'

May 27, 2026 8:43 AM

Stifel analyst Paul Matteis reiterated a Buy rating and $25.00 price target on Immunic Inc. (NASDAQ: IMUX).The analyst comments "Today ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found